<DOC>
	<DOCNO>NCT01224639</DOCNO>
	<brief_summary>The purpose study assess safety Takeda 's Tetravalent Dengue Vaccine Candidate ( TDV ) ( previously DENVax ) healthy adult give either subcutaneous ( SC ) intradermal ( ID ) injection two dose level ( low high ) . The vaccine give two dos 90 day apart . Safety assessment include injection site evaluation adverse event . The immune response generate vaccination assess 9 month first vaccination .</brief_summary>
	<brief_title>Safety Immunogenicity Study Assess TDV , Live Attenuated Tetravalent Vaccine Prevention Dengue Fever</brief_title>
	<detailed_description>This single center , placebo-controlled , randomize study assess safety tolerability two dose level ( low high ) TDV administer subcutaneously intradermally two dos separate interval 90 day . Initial dose low dose cohort perform Day 21 safety assess prior administration second dose low dose cohort Day 90 initial dose high dose cohort . Day 21 safety high dose cohort assess prior administration second dose cohort . Safety ( local injection site reaction solicit unsolicited adverse event ) assess Day 120 post-first ( 1 month second dose ) . Immunogenicity assess specified time point Day 120 post-prime ( 1 month second dose ) Days 180 270 ( 6 9 month post-first ) .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Is male female age 18 45 year , inclusive , time screening . Is good health determine medical history , physical examination , clinical safety laboratory examination . Has body mass index ( BMI ) range 1827 kilogram per square meter ( kg/m^2 ) . Has negative serology Human Immunodeficiency Virus ( HIV ) , Hepatitis C antibody , Hepatitis B surface antigen . Females child bear potential must negative urine pregnancy test result screen negative urine pregnancy test immediately prior vaccination willing use oral , implantable , transdermal injectable contraceptive another reliable mean contraception approve Investigator ( intrauterine device , female condom , diaphragm spermicidal , cervical cap , use condom sexual partner sterile sexual partner , abstinence ) screen last blood sample ( Day 270 ) . Is willing able give write informed consent participate . Is willing able communicate Investigator understand requirement study . Has condition would limit participant 's ability complete study . Clinically significant hematological , renal , hepatic , pulmonary , central nervous system , cardiovascular gastrointestinal disorder . Has abnormal electrocardiogram ( ECG ) . Has febrile illness ( temperature great equal ( &gt; = ) 38 degree Celsius ( °C ) 100.4 degree Fahrenheit ( °F ) moderate severe acute illness infection within three day vaccination . Diabetes mellitus . Has allergy penicillin , neomycin , streptomycin gentamicin . Hypersensitivity vaccine . Seropositivity four dengue serotypes ( TDV1 , TDV2 , TDV3 TDV4 ) , yellow fever ( YF ) virus West Nile ( WN ) virus . Has previous vaccination ( clinical trial approve product ) flaviviruses include dengue , YF WN . Has plan vaccination YF throughout duration study . Has receipt vaccine 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow vaccination study . Travel dengueendemic area two month prior study start plan travel dengueendemic area study period , include low altitude region Colombia dengue endemic . Known suspected congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month prior first vaccination , long term ( least 2 week within previous 3 month ) systemic corticosteroid therapy ( dose least 0.5 milligram per kilogram per day [ mg/kg/day ] ) prior first vaccination . Has history recur migraine prescription medication treatment recur headache migraine . Use nonsteroidal antiinflammatory drug ( NSAIDs ) , acetaminophen antihistamine 3 day immediately prior vaccination . Use prescription counter medication 7 day first vaccination ( Day 0 ) , exclude contraceptive painkiller contain NSAIDs acetaminophen , cold remedy , hormone replacement antihistamine . Positive urine screen cocaine , amphetamine , opiate , cannabinoids . Receipt investigational product participation clinical trial month first vaccination ( Day 0 ) conduct study . Receipt blood product immunoglobulins 8 week first vaccination ( Day 0 ) plan use study period . Donation blood 6 week first vaccination ( Day 0 ) time study . Females pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dengue fever</keyword>
	<keyword>live attenuate tetravalent dengue vaccine</keyword>
	<keyword>TDV</keyword>
	<keyword>Drug therapy</keyword>
</DOC>